Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 195.00 195.00 198.00 - 2,971 08:03:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 83.3 1,305

Syncona Share Discussion Threads

Showing 18776 to 18800 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
22/9/2020
09:07
All this good news, why is SYNC so meh?
1seanshare
22/9/2020
08:29
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the progression of GA that can lead to blindness.
brexitplus
09/9/2020
16:25
Ohhh, Autolus updated presentation with some nice new info on their website. Progress looks reasonable and getting numbers through the door now, 5 clinical trials now on the go on different cancer types.
luxaeterna1
07/9/2020
10:20
Hard to say, Autolus had some manufacturing challenges at the UK plant and had to modify the "open" to the "closed" process, that caused some inevitable delays & trial changes and definitely seemed to impact the price at the time. Since this time, the results have been publicly back on track. I think it's a classic volatile share & it depends what timebase you use. I mean seriously, you can optimistically say the share price has tripled since March 2020, or say it is down 25% since July 2020. Both are accurate stats.
luxaeterna1
05/9/2020
18:19
Does anyone know what AUTO has dropped. Is there bad news or just the market. SYNC also v low and no jump to the 285 level suggested a few weeks ago with the new NAV. AUTO presenting at ESMO this month which should give more info on progress.
greygrey
26/8/2020
12:43
Reading the Telegraph this morning I am assured that the future investment world belongs to pharmaceutical and Artificial Intelligence stocks. I happen to agree with them. What better then, to grab a handful with SYNC
chessman2
21/8/2020
22:05
It depends, Autolus is the major price driver here. It's fair to say many institutions have put a huge amount of money into Autolus. By 2022 they may have a saleable product - (was it adult ALL?). With the platform de-risked you can imagine how the MCAP will develop - but they do still have to demonstrate this, rather than just the theory. It seems like they will do it - but they do need to demonstrate volume and patient numbers in the Phase 3s. After that, well Freeline is a crazy proposition. It is either worth nothing, or £30bn (IMO) and that is a really scary idea. How do you value that? I have no idea. The haemophilia trials seem to be going well - but is it commercial? Needs another 2 years to get a real feel where Freeline is going.
luxaeterna1
13/8/2020
17:36
Thanks so much for the explanation. I am a little new to this but trying to learn. Problem was my online broker had not updated the NAV so I missed that. Pity it has not produced a price uplift as yet. As always we must be patient with this one though I do believe strongly in its long term potential.
greygrey
13/8/2020
15:27
The nav to end June (210.7p) was announced in the quarterly update on 10th August, since when the Freeline IPO brought a further uplift. The main bit of the IPO (8.8m shares) is done and dusted, the only bit outstanding is the option as is common in the US for the brokers to subscribe for up to a further 1.3m shares, and they have 30 days from 6th August. As this is also at $18, not much incentive for buyers to pay this with the price now a bit below, though they did trade over $21 on the first day so they may have drawn down a few more then.
tiger blue
13/8/2020
15:07
Ok many thanks Tiger Blue. I had thought NAV was updated quarterly and last was March but I must be mistaken. Do you know when the Freeline IPO closes by the way.
greygrey
13/8/2020
12:15
Thank you Greygrey. Having just given their quarterly update, Syncona won't issue another regular update on nav until the interim results to end Sept which last year came out on 21st November, so until then it's manual calculations based on the quoted stocks, exchange rates etc. The only exception would be where they do another funding round, when they will state the individual uplift (hopefully an uplift!) to their nav for the relevant company.
tiger blue
13/8/2020
11:59
Very helpful analysis. Th NAV update seems long overdue - any idea when it will be made. Also I guess the Freeline IPO has closed? so there should be an announcement about that soon. The price seems very stuck despite lots of positive news.
greygrey
13/8/2020
10:54
A few stats based on last night's close and the recent quarterly update: I estimate current nav at just over 221p, with cash of 108.25p now outweighed by the life science portfolio at 113p. As I forecast in February Freeline has now overtaken Autolus as the largest portfolio company, representing 37.6p per share vs Autolus 31.8p. Gyroscope and Achilles are both c 11p, and with the progress they are making and likely uplifts at future funding rounds the life sciences portfolio will become more diversified and inherently less risky when it is no longer dominated by one or two businesses. Swan Bio represents 5.2p and the CRT Pioneer Fund 6.3p, the remaining investments are c 10p per share. The quoted nav as usual looks understated, with so many investments still held at cost. With further funding rounds and the expected new investment in the macrophage cell therapy opportunity, there should also be less negative broker comment on the 'cash drag', though imho a strong capital base is reassuring and helps me sleep sounder in these incredibly difficult times.
tiger blue
13/8/2020
08:04
Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration
brexitplus
11/8/2020
15:07
This uplift seems very logical unless the premium to NAV reduces. I guess Freeline closes today although seems stuck at 16.50 ie below the 18 at which it was priced. I guess we’ll see in the next day or so.
greygrey
10/8/2020
07:12
Excellent update today. “Life science portfolio increases in value by 35% since year end: -- Net assets of GBP1,414.9 million, 210.7 p per share, a NAV return of 13.5 per cent in the period -- Life science portfolio valued at GBP677.0 million as at 30 June 2020, a return of 35.1 per cent in the period, with performance driven by the increase in the Autolus Therapeutics (Autolus) share price and the write-up of Freeline Therapeutics (Freeline) in its recent Series C financing -- Capital base of GBP737.9 million as at 30 June 2020; GBP29.2 million of capital deployed in the quarter Strong clinical progress with significant data generation and new programmes initiated.”
brexitplus
07/8/2020
17:30
When are we due a new NAV?
greygrey
07/8/2020
08:59
I am hopeful the resistance will shift up 15p, so the new upper resistance should be about 285p imminently.
luxaeterna1
07/8/2020
07:37
Syncona most certainly deliver...
ltinvestor
07/8/2020
07:30
Well there we go. Freeline IPO active and on the market today. Technically a £60m bump in NAV too, so perhaps a ~10p rise in Syncona MCAP. Good times
luxaeterna1
06/8/2020
14:43
Listened in to the conference call for AUTL. It is a competitive landscape but they clearly feel they have good potential for differentiated products, and compared to the competition the AUTL programs are demonstrating much lower toxicity so are better tolerated by patients with compromised immune systems.
tiger blue
06/8/2020
13:42
Nice financial and operational progress today from AUTO. Sounding more and more positive. 1st CAR-T trial allowing the patient to go home?!
luxaeterna1
05/8/2020
10:28
For those who subscribe to such theories, there was the classic 1 share trade yesterday pm. The UT trade of 50k plus at highest price of the day at close would suggest supply not meeting demand atm.
acuere
04/8/2020
13:47
Autolus announces changes to its Board and Management Team Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 2020.Dr. Backstrom currently serves as EVP, Head of Research & Development at Acceleron Pharma Inc (Acceleron) and prior to that served as Chief Medical Officer and Head of Regulatory Affairs at Celgene Corporation. Additionally, the Company announced that Dr. Nushmia Khokhar has been promoted to Senior Vice President, Clinical Development, and will take over the medical leadership role at Autolus. Dr. Khokhar is a board-certified oncologist with extensive early and late stage clinical development experience, having led several successful registration trials within the industry including the global daratumumab program at Janssen Oncology. Dr. Vijay Peddareddigari, Senior Vice President, Chief Medical Officer, is leaving the Company to return to the US.
brexitplus
04/8/2020
10:58
Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards. The newly appointed boards will help guide the development of the company's lead investigational gene therapy, GT005, a one-time therapy being developed to potentially slow the progression of dry age-related macular degeneration (AMD), as well as novel gene therapy delivery systems and additional pipeline candidates.
brexitplus
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220817 07:32:25